Minor non‐GI bleeding · patients with cancer with venous thromboembolism
Direct oral anticoagulant secondary prophylaxis probably leads to higher minor non‐GI bleeding compared with low molecular weight heparin secondary prophylaxis (moderate certainty).
1 finding from 1 review
All‐cause mortality · patients with active cancer with venous thromboembolism
Direct oral anticoagulant secondary prophylaxis showed no clear difference in all‐cause mortality compared with vitamin K antagonist secondary prophylaxis (low certainty).
1 finding from 1 review
Recurrent venous thromboembolism · patients with active cancer with venous thromboembolism
Direct oral anticoagulant secondary prophylaxis showed no clear difference in recurrent venous thromboembolism compared with vitamin K antagonist secondary prophylaxis (low certainty).
1 finding from 1 review
Adverse events associated with the use of anticoagulants (e.g. bleeding) ‐ not measured · sickle cell disease
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse events associated with the use of anticoagulants (e.g. bleeding) · people with sickle cell disease
Tinzaparin showed no clear difference in adverse events associated with the use of anticoagulants (e.g.… compared with placebo (low certainty).
1 finding from 1 review
Intervention not reported
Anticoagulants: events ‐ bleeding · patients with leading to fewer clinical adverse events
The intervention showed no clear difference in anticoagulants: events ‐ bleeding (low certainty).
1 finding from 1 review
Intervention not reported
Anticoagulants: events ‐ thromboembolism · patients with leading to fewer clinical adverse events
It is very uncertain whether the intervention changes anticoagulants: events ‐ thromboembolism (very low certainty).
1 finding from 1 review
Intervention not reported
Length of stay (days) ‐ oral anticoagulants · saving healthcare resources
1 finding from 1 review
Intervention not reported
Oral anticoagulants: time in target INR range (%) · patients with leading physiological parameters within therapeutic range
1 finding from 1 review
Intervention not reported
Time to achieve therapeutic range ‐ oral anticoagulants: time to achieve therapeutic prothrombin ratio (days) · patients with reducing time to achieve therapeutic control
1 finding from 1 review
Intervention not reported
Time to stabilization ‐ oral anticoagulants: time to stabilization (days) · patients with reducing time to achieve therapeutic control
1 finding from 1 review
All causes of mortality at 30 days · Anticoagulants in ACS
Factor Xa inhibitors showed no clear difference in all causes of mortality at 30 days compared with anticoagulants (high certainty).
1 finding from 1 review
All causes of mortality at 30 days ‐ UFH · Anticoagulants in ACS
Factor Xa inhibitors showed no clear difference in all causes of mortality at 30 days ‐ UFH compared with anticoagulants (high certainty).
1 finding from 1 review
All causes of mortality at 30 days ‐ Enoxaparin · Anticoagulants in ACS
Factor Xa inhibitors leads to lower all causes of mortality at 30 days ‐ Enoxaparin compared with anticoagulants (high certainty).
1 finding from 1 review
Major bleeding · Anticoagulants in ACS
Factor Xa inhibitors showed no clear difference in major bleeding at 30 days compared with anticoagulants (high certainty).
2 findings from 1 review
Major bleeding at 30 days ‐ Enoxaparin · Anticoagulants in ACS
Factor Xa inhibitors leads to higher major bleeding at 30 days ‐ Enoxaparin compared with anticoagulants (high certainty).
1 finding from 1 review
Minor bleeding · Anticoagulants in ACS
Factor Xa inhibitors showed no clear difference in minor bleeding at 30 days compared with anticoagulants (high certainty).
3 findings from 1 review
RR 0.7 [0.14, 3.39]
2 studies · 20404 participants
High
RR 1.76 [0.52, 5.94]
1 study · 326 participants
Moderate
RR 0.34 [0.28, 0.43]
1 study · 20078 participants
High
Antifibrinolytic agents (tranexamic acid (TXA) or epsilon aminocaproic acid (EACA)) vs Placebo, no intervention, or usual care
Outcome not reported · People on continuous direct oral anticoagulant (DOAC) treatment undergoing oral or dental procedures
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
0 studies
No studies found
Percentage of time within the therapeutic range · oral anticoagulant therapy in patients with atrial fibrillation
1 finding from 1 review
Anxiety · oral anticoagulant therapy in patients with atrial fibrillation
1 finding from 1 review